<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40982548</PMID><DateRevised><Year>2025</Year><Month>09</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2047-4881</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Sep</Month><Day>22</Day></PubDate></JournalIssue><Title>European journal of preventive cardiology</Title><ISOAbbreviation>Eur J Prev Cardiol</ISOAbbreviation></Journal><ArticleTitle>Benefit of Icosapent Ethyl Across Types and Sizes of Myocardial Infarction in REDUCE-IT.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">zwaf602</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/eurjpc/zwaf602</ELocationID><Abstract><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">We studied the efficacy and safety of icosapent ethyl (IPE) 4g daily in reducing the risk of myocardial infarction (MI) across different MI subtypes and sizes, among REDUCE-IT high-risk patients with hypertriglyceridemia.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">REDUCE-IT was a phase 3b, double-blind multicenter trial. Patients with established CVD or diabetes who were treated with statins and had moderate hypertriglyceridemia were randomized to receive IPE 4g daily or placebo. The current analysis focused on MI subtypes (fatal MI, nonfatal MI, ST-segment elevation MI (STEMI), non-STEMI (NSTEMI)), as well as MI size (measured by multiples of troponin upper limit of normal) and MI-related complications. Safety outcomes included treatment emergent adverse events (TEAEs), bleeding, atrial fibrillation, and flutter.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">At 5.7 years follow-up, MI incidence was lower with IPE compared with placebo (8.6% vs 12.0%), hazard ratio (HR) 0.69 (95% CI 0.58-0.81, P&lt;0.0001). STEMI incidence was lower with IPE (2.7% vs 3.9%, HR 0.60, 95% CI 0.44-0.81, P=0.0008), as was NSTEMI incidence (5.9% vs 7.8%, HR 0.73, 95% CI 0.60-0.89, P=0.001). Fatal and nonfatal MIs were reduced with IPE (HR 0.55, 95% CI 0.30-1.01, P=0.05 and HR 0.70, 95% CI 0.59-0.82, P&lt;0.0001, respectively). Stratification by size revealed IPE reduced most MIs, but the protective effect was higher for larger MIs (P&lt;0.0001). Further analyses showed benefits in MI-related outcomes, including reductions in spontaneous MI and MI-related complications. Among patients who developed MI, safety outcomes showed no significant increase in serious bleeding, atrial fibrillation or flutter, or adverse events with IPE.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">IPE significantly reduced MI across most subtypes and sizes in statin-treated patients with elevated triglycerides at increased cardiovascular risk.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">ClinicalTrials.gov Identifier NCT01492361.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2025. Published by Oxford University Press on behalf of the European Society of Cardiology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gurevitz</LastName><ForeName>Chen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhatt</LastName><ForeName>Deepak L</ForeName><Initials>DL</Initials><Identifier Source="ORCID">0000-0002-1278-6245</Identifier><AffiliationInfo><Affiliation>Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giugliano</LastName><ForeName>Robert P</ForeName><Initials>RP</Initials><AffiliationInfo><Affiliation>Brigham and Women's Hospital Heart and Vascular Center, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steg</LastName><ForeName>Ph Gabriel</ForeName><Initials>PG</Initials><AffiliationInfo><Affiliation>Universit&#xe9; Paris-Cit&#xe9;, INSERM-UMR1148, Assistance Publique-H&#xf4;pitaux de Paris, H&#xf4;pital Bichat, French Alliance for Cardiovascular Trials, and Institut Universitaire de France, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Michael</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-1679-2095</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Crescenz Veterans Affairs Medical Center and University of Pennsylvania School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brinton</LastName><ForeName>Eliot A</ForeName><Initials>EA</Initials><Identifier Source="ORCID">0000-0002-9807-4010</Identifier><AffiliationInfo><Affiliation>Utah Lipid Center, Salt Lake City, UT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jacobson</LastName><ForeName>Terry A</ForeName><Initials>TA</Initials><Identifier Source="ORCID">0000-0002-9926-2179</Identifier><AffiliationInfo><Affiliation>Lipid Clinic and Cardiovascular Risk Reduction Program, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ketchum</LastName><ForeName>Steven B</ForeName><Initials>SB</Initials><AffiliationInfo><Affiliation>Amarin Pharma, Inc., Bridgewater, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lira Pineda</LastName><ForeName>Armando</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Amarin Pharma, Inc., Bridgewater, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doyle</LastName><ForeName>Ralph T</ForeName><Initials>RT</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Amarin Pharma, Inc., Bridgewater, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giugliano</LastName><ForeName>Gabriella</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>University of Pittsburgh Medical Center, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mason</LastName><ForeName>R Preston</ForeName><Initials>RP</Initials><AffiliationInfo><Affiliation>Elucida Research, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tardif</LastName><ForeName>Jean-Claude</ForeName><Initials>JC</Initials><Identifier Source="ORCID">0000-0002-8200-8983</Identifier><AffiliationInfo><Affiliation>Montreal Heart Institute, Universit&#xe9; de Montr&#xe9;al, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martens</LastName><ForeName>Fabrice M A C</ForeName><Initials>FMAC</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Amsterdam University Medical Center, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ballantyne</LastName><ForeName>Christie M</ForeName><Initials>CM</Initials><Identifier Source="ORCID">0000-0002-6432-1730</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Baylor College of Medicine, and the Texas Heart Institute, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Budoff</LastName><ForeName>Matthew J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>David Geffen School of Medicine, Lundquist Institute, Torrance, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gibson</LastName><ForeName>C Michael</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Baim Clinical Research Institute, Boston, MA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01492361</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Prev Cardiol</MedlineTA><NlmUniqueID>101564430</NlmUniqueID><ISSNLinking>2047-4873</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><OtherAbstract Type="plain-language-summary" Language="eng"><AbstractText>Among patients at high risk for heart and vascular diseases who are receiving statins, icosapent ethyl (IPE) 4 g daily as an added treatment significantly lowers the risk of heart attack, also known as myocardial infarction (MI), across sizes and subtypes, including ST-segment elevation MI (STEMI) and non-STEMI (NSTEMI).In this secondary analysis of REDUCE-IT, IPE 4 g daily significantly reduced the risk of heart attack by 31% compared with placebo.IPE reduced incidence of large heart attacks by up to 65% and was associated with fewer related complications, including heart attack-related cardiac arrests and resuscitated heart attacks.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2025. Published by Oxford University Press on behalf of the European Society of Cardiology.</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">eicosapentaenoic acid</Keyword><Keyword MajorTopicYN="N">hypertriglyceridemia</Keyword><Keyword MajorTopicYN="N">icosapent ethyl</Keyword><Keyword MajorTopicYN="N">myocardial infarction</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>8</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>22</Day><Hour>18</Hour><Minute>36</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>22</Day><Hour>18</Hour><Minute>36</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>22</Day><Hour>13</Hour><Minute>44</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40982548</ArticleId><ArticleId IdType="doi">10.1093/eurjpc/zwaf602</ArticleId><ArticleId IdType="pii">8261596</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>